Marcelle D Smit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcelle D Smit has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Robert G. Tieleman
Department of Cardiology, Martini Hospital, Groningen, the Netherlands
3 shared publications - Michiel Rienstra
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
2 shared publications A Van Der Galiën
1 shared publicationAnne H Hobbelt
Department of Cardiology, University of Groningen, University Medical Centre Groningen , Groningen, PO Box 30.001, 9700 RB The Netherlands
1 shared publicationAnouk L de Ruiter
Dept of Cardiology, Martini Hospital Groningen, Van Swietenplein 1, Groningen 9728 NT, The Netherlands
1 shared publication- Bao-Oanh Nguyen
University Medical Centre Groningen
1 shared publication
Latest Publications
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (7)
Monitoring of ventricular rate in atrial fibrillation patients through an app based on pulse-plethysmography.
- 3 July 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (7)
Open AccessMonitoring of ventricular rate in atrial fibrillation patients through an app based on pulse-plethysmography.
- Open Access
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Rate control treatment with calcium channel blockers and beta blockers for patients with atrial fibrillation: a systematic review and meta-analysis
Aims: Controlling heart rate is a key objective in atrial fibrillation (AF) management, commonly achieved with beta blockers or non-dihydropyridine calcium channel blockers, both class I guideline recommendations. However, their long-term effectiveness has rarely been compared. This review aimed to critically evaluate all available evidence comparing these drug classes in AF treatment. Methods and results: We systematically searched MEDLINE, Embase, Web of Science, and Cochrane Central for original studies published up to 1 March 2025. Eligible studies included AF patients, compared calcium channel blockers and beta blockers, and reported heart rate or other clinically relevant outcomes. The primary outcome was 24-hour heart rate on Holter monitoring. Meta-analyses were performed where data were sufficiently homogeneous. Of 1906 identified records, 25 met inclusion criteria. Five studies reported 24-h mean heart rate, showing no difference between drug classes (mean difference: 3.6 b.p.m., 95% CI: −2.9 to 10.1, P = 0.274). Eight studies reported maximum exercise heart rate, which was significantly higher with calcium channel blockers than with beta blockers (mean difference: 10.5 b.p.m., 95% CI: 3.3 to 17.7, P = 0.043). Other outcomes were too heterogeneous for meta-analysis, though three studies reported increased peak oxygen uptake with calcium channel blockers. Conclusion: Calcium channel blockers and beta blockers provide comparable control of mean heart rate in AF. However, patients on calcium channel blockers have a higher maximum heart rate during exercise. In our qualitative synthesis, some studies reported higher peak oxygen uptake calcium channel blocker treated patients, these results should be seen as hypothesis generating.
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Open AccessRate control treatment with calcium channel blockers and beta blockers for patients with atrial fibrillation: a systematic review and meta-analysis
Aims: Controlling heart rate is a key objective in atrial fibrillation (AF) management, commonly achieved with beta blockers or non-dihydropyridine calcium channel blockers, both class I guideline recommendations. However, their long-term effectiveness has rarely been compared. This review aimed to critically evaluate all available evidence comparing these drug classes in AF treatment. Methods and results: We systematically searched MEDLINE, Embase, Web of Science, and Cochrane Central for original studies published up to 1 March 2025. Eligible studies included AF patients, compared calcium channel blockers and beta blockers, and reported heart rate or other clinically relevant outcomes. The primary outcome was 24-hour heart rate on Holter monitoring. Meta-analyses were performed where data were sufficiently homogeneous. Of 1906 identified records, 25 met inclusion criteria. Five studies reported 24-h mean heart rate, showing no difference between drug classes (mean difference: 3.6 b.p.m., 95% CI: −2.9 to 10.1, P = 0.274). Eight studies reported maximum exercise heart rate, which was significantly higher with calcium channel blockers than with beta blockers (mean difference: 10.5 b.p.m., 95% CI: 3.3 to 17.7, P = 0.043). Other outcomes were too heterogeneous for meta-analysis, though three studies reported increased peak oxygen uptake with calcium channel blockers. Conclusion: Calcium channel blockers and beta blockers provide comparable control of mean heart rate in AF. However, patients on calcium channel blockers have a higher maximum heart rate during exercise. In our qualitative synthesis, some studies reported higher peak oxygen uptake calcium channel blocker treated patients, these results should be seen as hypothesis generating.
- Open Access
- 13 November 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (6) , 910-920
Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
The Routine vs. Aggressive risk factor driven upstream rhythm Control for prevention of Early persistent atrial fibrillation (AF) in heart failure (HF) (RACE 3) trial demonstrated that targeted therapy of underlying conditions improved sinus rhythm maintenance at 1 year. We now explored the effects of targeted therapy on the additional co-primary endpoints; sinus rhythm maintenance and cardiovascular outcome at 5 years. Patients with early persistent AF and mild-to-moderate stable HF were randomized to targeted or conventional therapy. Both groups received rhythm control therapy according to guidelines. The targeted group additionally received four therapies: angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ARBs), statins, mineralocorticoid receptor antagonists (MRAs), and cardiac rehabilitation. The presence of sinus rhythm and cardiovascular morbidity and mortality at 5-year follow-up were assessed. Two hundred and sixteen patients consented for long-term follow-up, 107 were randomized to targeted and 109 to conventional therapy. At 5 years, MRAs [76 (74%) vs. 10 (9%) patients, P < 0.001] and statins [81 (79%) vs. 59 (55%), P < 0.001] were used more in the targeted than conventional group. Angiotensin-converting enzyme inhibitors/ARBs and physical activity were not different between groups. Sinus rhythm was present in 49 (46%) targeted vs. 43 (39%) conventional group patients at 5 years (odds ratio 1.297, lower limit of 95% confidence interval 0.756, P = 0.346). Cardiovascular mortality and morbidity occurred in 20 (19%) in the targeted and 15 (14%) conventional group patients, P = 0.353. In patients with early persistent AF and HF superiority of targeted therapy in sinus rhythm maintenance could not be preserved at 5-year follow-up. Cardiovascular outcome was not different between groups. Clinicaltrials.gov NCT00877643.
- 13 November 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (6) , 910-920
Open AccessLong-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
The Routine vs. Aggressive risk factor driven upstream rhythm Control for prevention of Early persistent atrial fibrillation (AF) in heart failure (HF) (RACE 3) trial demonstrated that targeted therapy of underlying conditions improved sinus rhythm maintenance at 1 year. We now explored the effects of targeted therapy on the additional co-primary endpoints; sinus rhythm maintenance and cardiovascular outcome at 5 years. Patients with early persistent AF and mild-to-moderate stable HF were randomized to targeted or conventional therapy. Both groups received rhythm control therapy according to guidelines. The targeted group additionally received four therapies: angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ARBs), statins, mineralocorticoid receptor antagonists (MRAs), and cardiac rehabilitation. The presence of sinus rhythm and cardiovascular morbidity and mortality at 5-year follow-up were assessed. Two hundred and sixteen patients consented for long-term follow-up, 107 were randomized to targeted and 109 to conventional therapy. At 5 years, MRAs [76 (74%) vs. 10 (9%) patients, P < 0.001] and statins [81 (79%) vs. 59 (55%), P < 0.001] were used more in the targeted than conventional group. Angiotensin-converting enzyme inhibitors/ARBs and physical activity were not different between groups. Sinus rhythm was present in 49 (46%) targeted vs. 43 (39%) conventional group patients at 5 years (odds ratio 1.297, lower limit of 95% confidence interval 0.756, P = 0.346). Cardiovascular mortality and morbidity occurred in 20 (19%) in the targeted and 15 (14%) conventional group patients, P = 0.353. In patients with early persistent AF and HF superiority of targeted therapy in sinus rhythm maintenance could not be preserved at 5-year follow-up. Cardiovascular outcome was not different between groups. Clinicaltrials.gov NCT00877643.